Jazz Pharmaceuticals(JAZZ) - 2023 Q1 - Earnings Call Presentation
Jazz Pharmaceuticals(JAZZ)2023-05-16 18:3413 d | --- | --- | --- | --- | --- | --- | |---------------|-----------------------------------|----------------------------------------------------------------|-------------------------------------|---------|-----------------------------------------------------------| | | | | EMAS | | Phase 3 Initiated - Fourth target indication | | Epidiolex | | | Japan (LGS/TSC/DS) | | Phase 3 First Patient Enrolled | | JZP150 | PTSD | | | | Phase 2 Top-line Data Readout expected late 2023 | | Suvecaltamide | Phase 2b es ...